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Abstract 
AIM: This study was conducted to identify malondialdehyde (MDA) serum level, nerve growth factor (NGF) serum 
level, diabetic peripheral neuropathy score and the correlation between MDA and NGF serum level with diabetic 
peripheral neuropathy score. 
METHODS: A cross-sectional study was conducted to observe diabetic patients in the internal medicine 
department in Dr M. Djamil Hospital, Padang, Indonesia. The MDA serum level was measured using Beuge 
method with thiobarbituric acid. The NGF serum level was analysed using ELISA method. Diabetic peripheral 
neuropathy score was defined when history score in Michigan Neuropathy Screening Instrument (MNSI) ≥ 7 and 
physical assessment score in MNSI > 2. 
RESULTS: Thirty subjects with diabetes has diabetic peripheral neuropathy score 3.53 (± 0.91), MDA serum level 
2.16 (± 2.89) nmol/ml, and NGF serum level 10.56 (± 2.89) pg/dl. There were significant correlations between the 
MDA serum level and the diabetic peripheral neuropathy score (r = 0.364, p = 0.048), and between the NGF 
serum level with the diabetic peripheral neuropathy score (r = -0.59, p = 0.001). 
CONCLUSION: There are high MDA serum level and low NGF serum level in patients with diabetic peripheral 
neuropathy. Low NGF serum level plays a bigger role than high MDA serum level in diabetic peripheral 
neuropathy. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Diabetes mellitus is a chronic disease that 
may cause a long term health problem and multiple 
quality of life depriving complications. One of the 
diabetic complications is diabetic peripheral 
neuropathy that can be assessed by Minnesota 
Neuropathy Screening Instrument (MNSI). The MNSI 
includes two separate assessments, a 15-item self-
administered questionnaire and a lower extremity 
examination. Diabetic peripheral neuropathy is based 
on the existence of chronic hyperglycemia. Chronic 
hyperglycemia is associated with oxidative stress, 
endothelium damages, and it causes microvascular 
and hemorheological disturbances [1], [2]. 
Oxidative stress can be determined by several 
ways, such as MDA. MDA is one of recommended 
marker for oxidative stress. MDA, a product of the lipid 
peroxidation, has been accepted as one of the reliable 
biological markers for oxidative stress, based on BOS 
(Biomarker Oxidative Stress) Study in 2002 [3], [4], 
[5]. MDA has been documented as a primary 
biomarker of free radical-mediated lipid damage and 
oxidative stress. Increased MDA level in serum and 
may other tissues have been reported in diabetic 
patients. MDA may impact peripheral nerve among 
diabetic patients [6], [7]. 
NGF is an important protein to maintain life 
and survival of the neurons, and it works by increasing 
cell regeneration and decreasing the degeneration. 
NGF decline level is associated with the disturbances 
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in Schwann cells regeneration because NGF 
produced by the neurons and the Schwann cells. NGF 
decline level induces peripheral nerve lesions in 
diabetic patients. The forms of lesions are axonal 
atrophy, demyelination, and reduced number of nerve 
fibres [8], [9]. Pittinger and Vinik (2003) found that a 
decrease of NGF serum level in diabetes correlates 
with the clinical symptoms of neuropathy [10]. The 
clinical symptoms of diabetic neuropathy can be 
assessed with diabetic peripheral neuropathy score by 
Minnesota Neuropathy Screening Instruments (MNSI) 
[11]. 
The objective of this study is to identify MDA 
serum level, NGF serum level, diabetic peripheral 
neuropathy score and the correlation between MDA 
and NGF serum level with diabetic peripheral 
neuropathy score. 
 
 
Methods 
 
This was a cross-sectional study, conducted 
in the internal medicine department in Dr M. Djamil 
Hospital, Padang, West Sumatera, Indonesia. This 
study was conducted from January 2017 until 
December 2017. 
Inclusion criteria in this study are type 2 
diabetes mellitus (T2DM) patients with peripheral 
neuropathy, aged between 18 to 59 years old that has 
agreed to participate and signed the informed consent 
form. 
Exclusion criteria in this study are patients 
with chronic renal disease, liver cirrhosis, stroke, 
Alzheimer's disease, allergic disease, rheumatoid 
arthritis, psoriatic arthritis, systemic lupus 
erythematosus, systemic sclerosis and other 
autoimmune disorder, leprosy, anemia, 
thrombocytosis, patients currently using 
antituberculosis drugs, cytostatic drug, steroid, 
alcohol, and patients with foot ulcer that is difficult to 
examine. 
The diabetic peripheral neuropathy score was 
calculated by history score in MNSI score ‘7’ or higher 
and physical assessment score in MNSI more than 
two. The history score in MNSI is a self-fulfilled 
questionnaire. Physical assessment in MNSI was the 
appearance of feet, ulceration, ankle reflexes, 
vibration perception at great toe, and monofilament 
[6]. The appearance of feet was scored 1 when there 
was deformities, dry skin, callus, infection, fissure. 
Ulceration was score 1 when present, and 
scored 0 if absent. 
The ankle reflexes, also known as the Achilles 
reflex, examined by tapped the Achilles tendon while 
the foot is dorsiflexed. When there was no reflex, they 
would get score 1, when the reflex which appeared 
only after assisted by Jendrassic manoeuvre, they 
would get score 0.5. 
Vibration perception at great toe was 
examined by placing the fork on the projection of distal 
interphalangeal joint of the hallux. Subjects would tell 
the examiner whether they felt the vibration when it 
disappeared with closed eyes. When subjects did not 
report any vibration, the score was zero. When the 
subjects felt the vibration less than 10 seconds, they 
would get score 0.5. 
The monofilament testing was done on ten 
points in each foot. The monofilament was 
perpendicular and pressed for two seconds only, while 
the subjects closed their eyes. All points would be 
tested for three times. Score zero would be given for 
eight right answers or more, and a half point for one to 
seven right answers. 
MDA and NGF serum level were measured by 
laboratory methods. About 3 mL blood samples were 
taken from the cubital vein using an anticoagulant-free 
container to examine MDA and NGF serum levels. 
MDA serum level was measured by using Beuge 
method with thiobarbituric acid, while NGF serum level 
was measured by using the ELISA method for human 
nerve growth factor-β. 
The numerical data would be presented as 
mean and standard deviation. Data were analysed 
using Statistical Package for Social Sciences (SPSS) 
22.0. The normality test was performed only for the 
numerical data using the Kolmogorov-Smirnov test. 
Correlation between MDA and NGF serum levels with 
peripheral diabetic neuropathy score were examined 
using the Spearman correlation test. The coefficient 
correlation was calculated and the level of significance 
for the correlation was counted. The level of statistical 
significance was 5%. 
 
 
Results 
 
Patient’s age in this study ranged from 41 to 
59 years old. The range of the MDA serum level in this 
study was between 1.6 nmol/mL to 3.01 nmol/ml while 
the NGF serum level ranged from 6.8 pg/dl up to 15.7 
pg/dl. The peripheral diabetic neuropathy score in this 
study is 3.53 (± 0.91) 
Table 1: Characteristics of the subjects 
Variable n (%) mean (SD) 
Age (years)  53.9 (5.7) 
Sex 
Male 13 (43)  
Female 17 (57)  
Body Mass Index (Kg/m
2
)  24.6 (3.7) 
HbA1c (%)  8.8 (2.0) 
Neuropathy score  3.53 (0.91) 
MDA (nmol/mL)  2.16 (0.28) 
NGF (pg/dL)  10.56 (2.89) 
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Figure 1: Correlation between the MDA serum level and the diabetic 
peripheral neuropathy score (r = 0.364 and p = 0.048) 
 
There was a positive correlation (r = 0.364, p 
= 0.048) proved between the MDA serum level with 
diabetic peripheral neuropathy score (Figure 1). The 
correlation between NGF serum level and diabetic 
peripheral neuropathy score was r = -0.59 and p = 
0.001 (Figure 2). 
 
Figure 2: Correlation between NGF serum level and diabetic 
peripheral neuropathy score (r = -0.59 and p = 0.001) 
 
 
Discussion 
 
The mean MDA serum level of this study was 
higher than normal. Maitreyess (2011) and Martin-
Gallan (2003) has also found that MDA serum level on 
T2DM with complication was higher than the no 
complication group [12], [13]. Bhutia (2011) and Jalees 
(2017) found that the MDA serum level was 
significantly elevated in patients with diabetes 
compared to those in normal subjects [14], [15]. 
Zavar-Reza (2014) observed significant increased 
MDA serum level in T2DM patients with complications 
[16]. Increased MDA serum level can be explained by 
increasing oxidative stress in diabetic patients. 
Increased level of oxidative stress associated with free 
radical-mediated lipid peroxidation. MDA serum level 
increased because of free oxygen radicals in diabetes 
that cause peroxidative breakdown of phospholipids. 
In this study, the mean serum level of NGF 
was lower than normal. Mahmoud et al. in 2009 found 
a significant lower NGF serum level among patients 
with peripheral neuropathy [17]. Obrosova et al., 
(2001) had shown that NGF serum level in the 
diabetic patient was lower than the control [18]. Tosaki 
et al., (2008) reported that the Schwann cell planted 
on high-glucose culture media had a low 
concentration of NGF [19]. Yilmaz et al., (2013) 
obtained the result of lower NGF production by the 
Schwann cell of diabetic subjects [20]. NGF decline 
level is associated with the disturbances in Schwann 
cells regeneration because NGF produced by the 
neurons and the Schwann cells. The oxidative stress 
that occurs in diabetic patients will diminish the 
nutrient and oxygen supply for the nerve cells, 
resulting in interfering the life of the nerve and the 
Schwann cells and increasing the cell degeneration 
[2], [21]. 
In this study, we found a positive correlation 
between MDA serum level with diabetic peripheral 
neuropathy score. Aziza (2014) found that an increase 
of MDA serum level in diabetic neuropathy rats [22]. 
Martinez-Hevaz (2017) reported that altered in MDA 
values is associated with polyneuropathy in diabetic 
patients [23]. 
We found a significant negative correlation 
between NGF serum level with diabetic peripheral 
neuropathy score. Yasuda et al., (2003) discovered a 
positive correlation between decreasing NGF serum 
level and the neuron regeneration. NGF regulates 
intraneural homeostasis during development by 
providing neurotrophic and regulating intracellular 
pathways to promote neuronal sprouting [11]. Li 
(2017) showed that NGF has a protective effect in 
diabetic peripheral neuropathy [24]. 
In conclusion, there is a high MDA serum 
level and low NGF serum level in patients with 
diabetic peripheral neuropathy. Low NGF serum level 
play a bigger role than high MDA serum level in 
diabetic peripheral neuropathy. 
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